Latest Coronavirus News
Merck's experimental COVID-19 antiviral pill appears effective, but may pose risks for pregnant women, including birth defects and toxicity to developing fetuses, according to the U.S. Food and Drug Administration.
On Friday morning Merck announced updated results from its molnupiravir study that showed a smaller benefit than first thought: Among more than 1,400 adults in a company study, the drug reduced the combined risk of hospitalization and death by 30 percent, less than the 50 percent first reported.
Nearly 7 percent of patients who received Merck's drug within five days of COVID-19 symptoms ended up in the hospital and one died. That compared to 10 percent of patients hospitalized who were taking a placebo and nine deaths.
Potential risks were also identified in animal studies of molnupiravir, according to an analysis by FDA scientists. The agency's report was posted in advance of a meeting Tuesday of the FDA's outside experts who will weigh emergency use of the pill.
Based on its findings, the FDA will ask its expert panel whether the pill should never be given during pregnancy or if it could be used in certain situations where the benefits outweigh the risks. Given the safety concerns, FDA scientists said Merck agreed the drug would not be used in children.
The agency isn't required to follow the advice of its advisory panels, but it typically does.
If authorized, the pills would be the first that U.S. patients could take at home to ease symptoms and speed recovery. It is already authorized for emergency use in the U.K.
Molnupiravir works by inserting tiny mutations into the coronavirus' genetic code to stop the virus from reproducing.
The FDA scientists did note that the drug causes small changes in the spike protein used by the coronavirus to penetrate human cells, and theoretically those changes could lead to dangerous new variants, the AP reported.
Visit the U.S. Food and Drug Administration for more on COVID treatments.
Robert Preidt and Robin Foster
Copyright © 2021 HealthDay. All rights reserved.